Core Viewpoint - 微泰医疗-B's LinX continuous glucose monitoring system has received market approval in India, marking a significant entry into a high-growth market with substantial diabetes management needs [1] Company Summary - The LinX system is recognized for its superior performance and reliability, having been integrated into healthcare systems across multiple European countries and gaining access in emerging markets in the Middle East, Asia-Pacific, and South America [1] - The approval in India is expected to greatly expand the company's international market reach, laying a solid foundation for scaling international operations and revenue growth [1] Industry Summary - The global continuous glucose monitoring market is experiencing strong growth, with India representing a core emerging market with vast potential [1] - According to the IDF's 2025 Global Diabetes Map, there are approximately 89.83 million diabetes patients aged 20-79 in India, with a prevalence rate of 9.5%, ranking second globally [1] - The rising prevalence of prediabetes and the trend of younger patients indicate a significant gap in diabetes management systems, creating urgent demand for digital and intelligent diabetes management solutions [1] - The company's focus on global development in diabetes monitoring, treatment, and management will continue to drive innovation in related technologies and products [1]

Core Viewpoint - The company, MicroTech Medical-B (02235), has received approval for its LinX continuous glucose monitoring system in India, marking a significant entry into a high-growth market with substantial diabetes prevalence [1][2]. Group 1: Product Approval and Market Entry - The LinX system has been approved for continuous glucose monitoring in adults in India, enhancing the company's international market presence [1]. - The system has already been integrated into healthcare systems across multiple European countries and has gained access in emerging markets in the Middle East, Asia-Pacific, and South America [1]. Group 2: Market Potential and Demand - India has approximately 89.83 million diabetes patients aged 20-79, with a prevalence rate of 9.5%, ranking second globally in terms of patient numbers [1]. - The country also faces a significant increase in prediabetes rates and a concerning trend of younger individuals being affected, indicating a substantial demand for digital and intelligent diabetes management solutions [1]. Group 3: Future Focus - The company plans to continue focusing on the global development of diabetes monitoring, treatment, and management, while driving innovation in related technologies and products [2].

Core Viewpoint - The company has received approval for its LinX continuous glucose monitoring system in India, marking a significant entry into a high-growth market with substantial diabetes prevalence [1]. Group 1: Product Approval and Market Entry - The LinX system has been approved for continuous glucose monitoring in adults in India, enhancing the company's international market presence [1]. - The system has already been integrated into healthcare systems across multiple European countries and has gained access in emerging markets in the Middle East, Asia-Pacific, and South America [1]. Group 2: Market Potential and Demand - India has approximately 89.83 million diabetes patients aged 20-79, with a prevalence rate of 9.5%, ranking second globally [1]. - The country also has the highest number of diabetes-related deaths, indicating a critical need for effective diabetes management solutions [1]. - The rising prevalence of prediabetes and the trend of younger patients highlight a significant gap in the current healthcare system, creating urgent demand for digital and intelligent diabetes management solutions [1]. Group 3: Future Focus - The company plans to continue focusing on the global development of diabetes monitoring, treatment, and management, driving innovation in related technologies and products [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 MicroTech Medical (Hangzhou) Co., Ltd. 微 泰 醫 療 器 械（ 杭 州 ）股 份 有 限 公 司 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號： 2235） 自願性公告 本公司持續葡萄糖監測系統海外獲批 本公告乃微泰醫療器械（杭州）股份有限公司（「本公司」及其附屬公司，「本集 團」）自願發佈，以向本公司股東及潛在投資者提供有關本集團的最新發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，我們的LinX（AiDEX X的國際品 牌名）持續葡萄糖監測系統，近期獲得印度的上市批准，適用於成人的連續動 態血糖監測。LinX系統憑藉其卓越性能與可靠性，不僅成功納入歐洲多國醫療 保障體系，亦在中東、亞太及南美等新興市場完成多國准入，構築了多元化、 可持續的國際業務支撐體系。 近年來，全球持續葡萄糖監測市場呈現強勁增長態勢。印 ...

格隆汇11月26日丨微泰医疗-B(02235.HK)公告，11月26日耗资25.8万港元回购3.9万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 微泰醫療器械（杭州）股份有限公司（於中華人民共和國註冊成立） 呈交日期： 2025年11月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02235 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有 ...

微泰医疗-B(02235)发布公告，于2025年11月25日斥资34.7万港元回购5.24万股。 ...

智通财经APP讯，微泰医疗-B(02235)发布公告，于2025年11月25日斥资34.7万港元回购5.24万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2025年11月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02235 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不 ...

Summary of Key Points Core Viewpoint - A total of 36 companies conducted share buybacks on November 24, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent on buybacks. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 1.022 million shares for a total of 636 million yuan, representing 0.825% of its total share capital for the year [1][2]. - China COSCO Shipping (01919) repurchased 3 million shares for 40.35 million yuan, accounting for 1.604% of its total share capital [2]. - China International Marine Containers (02039) repurchased 4.8904 million shares for 35.9467 million yuan, which is 1.530% of its total share capital [2]. Group 2: Other Notable Buybacks - China Feihe (06186) repurchased 7.233 million shares for 29.9668 million yuan, representing 1.969% of its total share capital [2]. - Sinopec Limited (00386) repurchased 4.054 million shares for 17.7861 million yuan, which is 0.150% of its total share capital [2]. - Pacific Basin Shipping (02343) repurchased 5 million shares for 12.757 million yuan, accounting for 1.555% of its total share capital [2]. Group 3: Smaller Buybacks - MONGOL MINING (00975) repurchased 390,000 shares for 3.6551 million yuan, which is 0.124% of its total share capital [2]. - Miniso Group (09896) repurchased 866,800 shares for 31.938 million yuan, representing 0.372% of its total share capital [2]. - Weigao Group (01066) repurchased 40,000 shares for 211,600 yuan, accounting for 4.379% of its total share capital [3].